Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hemato
Special Issues
Stem Cells and Therapy: A Themed Honorary Issue to Prof....
share announcement

Stem Cells and Therapy: A Themed Honorary Issue to Prof. Luc Douay

A special issue of Hemato (ISSN 2673-6357). This special issue belongs to the section "Plasma Cell Disorders".

Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 6334

Special Issue Editor

Dr. Michèle Sabbah

E-Mail Website
Guest Editor
Sorbonne Université, INSERM U938, Centre de Recherche Saint-Antoine, F-75012 Paris, France
Interests: cancer; myeloma; mesenchymal stem cells; signaling pathways; differenciation

Special Issue Information

Dear Colleagues,

This Special Issue of Hemato will contain manuscripts from leading scientists throughout the world to honor Prof. Luc Douay for his outstanding contributions in the field of hematopoietic stem cells and its application to cell therapy. Prof. Luc Douay has largely contributed in the concept of cultured red blood cells (cRBC) generated in vitro from stem cells for transfusion purposes and first described all the major steps. In recent decades, there has been an explosion of interest in stem cell in both basic and translational research, which has now penetrated all areas of modern biology, offering new perspectives on developmental disorders, including cancer. In this Special Issue, we aim to highlight some of the most important and topical issues—including recent advances, controversies, and challenges in stem cell research, and of course their clinical implications. New tools, such as organoid culture and single cell technologies; novel methods and new protocols improving cells for regenerative purposes and studying stem cell aging and cancer; and new therapies based on stem cell transplantation or endogenous stem cells will be presented. Each contribution should reflect the spirit and the main objective that has guided Prof. Luc Douay, the successful transfer of the innovative concept from Bench to Bed.

Dr. Michèle Sabbah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Stem cells
  • Regenerative medicine
  • Cancer stem cells
  • Stem cell technology
  • Molecular biology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 14965 KiB  
Article
Human Bone Marrow Mesenchymal Stromal Cell-Derived CXCL12, IL-6 and GDF-15 and Their Capacity to Support IgG-Secreting Cells in Culture Are Divergently Affected by Doxorubicin
by Gintare Lasaviciute, Anna Höbinger, Dorina Ujvari, Daniel Salamon, Aisha Yusuf, Mikael Sundin, Eva Sverremark-Ekström, Rayan Chikhi, Anna Nilsson and Shanie Saghafian-Hedengren
Hemato 2021, 2(1), 154-166; https://doi.org/10.3390/hemato2010009 - 13 Mar 2021
Viewed by 2442
Abstract
Various subsets of bone marrow mesenchymal stromal cells (BM MSCs), including fibroblasts, endothelial, fat and reticular cells, are implicated in the regulation of the hematopoietic microenvironment and the survival of long-lived antibody-secreting cells (ASCs). Nowadays it is widely acknowledged that vaccine-induced protective antibody [...] Read more.
Various subsets of bone marrow mesenchymal stromal cells (BM MSCs), including fibroblasts, endothelial, fat and reticular cells, are implicated in the regulation of the hematopoietic microenvironment and the survival of long-lived antibody-secreting cells (ASCs). Nowadays it is widely acknowledged that vaccine-induced protective antibody levels are diminished in adults and children that are treated for hematological cancers. A reason behind this could be damage to the BM MSC niche leading to a diminished pool of ASCs. To this end, we asked whether cell cytotoxic treatment alters the capacity of human BM MSCs to support the survival of ASCs. To investigate how chemotherapy affects soluble factors related to the ASC niche, we profiled a large number of cytokines and chemokines from in vitro-expanded MSCs from healthy donors or children who were undergoing therapy for acute lymphoblastic leukemia (ALL), following exposure to a widely used anthracycline called doxorubicin (Doxo). In addition, we asked if the observed changes in the measured soluble factors after Doxo exposure impacted the ability of the BM niche to support humoral immunity by co-culturing Doxo-exposed BM MSCs with in vitro-differentiated ASCs from healthy blood donors, and selective neutralization of cytokines. Our in vitro results imply that Doxo-induced alterations in BM MSC-derived interleukin 6 (IL-6), CXCL12 and growth and differentiation factor 15 (GDF-15) are not sufficient to disintegrate the support of IgG-producing ASCs by the BM MSC niche, and that serological memory loss may arise during later stages of ALL therapy. Full article
(This article belongs to the Special Issue Stem Cells and Therapy: A Themed Honorary Issue to Prof. Luc Douay)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 366 KiB  
Review
Impaired Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation: Its Pathogenesis and Potential Treatments
by Masahiro Imamura
Hemato 2021, 2(1), 43-63; https://doi.org/10.3390/hemato2010002 - 2 Jan 2021
Cited by 3 | Viewed by 3237
Abstract
Impaired hematopoiesis is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Bone marrow aplasia and peripheral cytopenias arise from primary and secondary graft failure or primary and secondary poor graft function. Chimerism analysis is useful to discriminate these conditions. By determining [...] Read more.
Impaired hematopoiesis is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Bone marrow aplasia and peripheral cytopenias arise from primary and secondary graft failure or primary and secondary poor graft function. Chimerism analysis is useful to discriminate these conditions. By determining the pathogenesis of impaired hematopoiesis, a timely and appropriate treatment can be performed. Hematopoietic system principally consists of hematopoietic stem cells and bone marrow microenvironment termed niches. Abnormality in hematopoietic stem and progenitor cells and/or abnormality in the relevant niches give rise to hematological diseases. Allo-HSCT is intended to cure each hematological disease, replacing abnormal hematopoietic stem cells and bone marrow niches with hematopoietic stem cells and bone marrow niches derived from normal donors. Therefore, treatment for graft failure and poor graft function after allo-HSCT is required to proceed based on determining the pathogenesis of impaired hematopoiesis. Recent progress in this area suggests promising treatment manipulations for graft failure and poor graft function. Full article
(This article belongs to the Special Issue Stem Cells and Therapy: A Themed Honorary Issue to Prof. Luc Douay)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop